Clinical Trial Update: A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating the combination of ipilimumab and nivolumab in patients with recurrent glioma with elevated tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Idh-mutant
• Diffuse Glioma
• Glioblastoma
• Glioblastoma Idh-wildtype

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma | Phase 2 | Status: ACTIVE_NOT_RECRUITING